



PATENT  
512425-2093 **516745-200.1** *JPW*

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Lal et al  
U.S. Serial No. : 10/611,539  
Filing Date : July 1, 2003  
For : **INHIBITORS OF CYCLIN-DEPENDENT KINASES  
AND THEIR USE**  
Group Art Unit : 1632  
Confirmation No. : 4710

745 Fifth Avenue  
New York, NY 10151

FIRST CLASS MAIL

I hereby certify that this correspondence is being  
deposited with the United States Postal Service  
as first class mail in an envelope addressed to:

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

William F. Lawrence, Reg. No. 28,029

Name of Applicant, Assignee or Registered Representative

*William F. Lawrence*  
Signature

*May 10, 2004*  
Date of Signature

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Enclosed are copies of publications, the subject matters of which are mentioned  
in the specification for the Examiner's review:

1. US 5,723,313, March 3, 1998, Sherr et al;
2. US 5,733,920, March 31, 1998, Mansuri et al;

3. US 5,849,733, December 15, 1998, Kim;
4. US 5,116,954, May 26, 1992, Briet et al;
5. US 5,284,856, February 8, 1994, Naik et al;
6. US H1427, April 4, 1995, Briet et l;
7. US 4,900,727, February 13, 1990; Kattige et al;
8. WO 01/83469 A1, published November 8, 2001;
9. Senderowicz et al, "Preclinical and Clinical Development of Cyclin-Dependent Kinease Modulators"; J. Natl. Cancer Institute, 2000, 376-387;
10. Naik et al, "An Anti-Inflammatory Cum Immunomodulatory Piperidinylnbenzopyranone from *Dyoxylum Binectariferum*: Isolation, Structure and Total Synthesis"; Tetrahedron, 1998, 44(7), 2081-2086;
11. Pérez-Roger et al, "Inhibition of Cellular Proliferation by Drug Targeting of Cyclin-Dependent Kinases"; Curr. Pharm. Biotechnol, 2000; July 1 (1), 107-116;
12. Losiewocz et al, "Potent Inhibition of CDC2 Kinase Activity by the Flavonoid L86-8275"; Biochemical and Biophysical Research Communicaitons", 1994,589-595;
13. J. Org. Chem. 1992, 57, 6321-6323;
14. Larget et al, "Conveneint Extension of the Wessely-Moser Rearangement for the Synthesis of substituted Alkylaminoflavones as Neuroprotective Agents in Vitro"; Bioorganic and Medicinal Chemistry Letters 10 (2000) 835-838;
15. Tsuritani et al; Organic Letters 2001, Vol. 3, No. 17, 2709-2711;
16. Bang-Chi-Chen et al, "A New Facile Method for the Synthesis of 1-Arylimidazoles-5-Carboxylates", Tetrahedron Letters 41 (2000) 5453-5456;

17. Falb et al, "A Convenient Synthesis of Chiral Oxazolidin-2-Ones and Thiazolidin-2-Ones and an Improved Preparation of Triphosgene"; Synthetic Communications, 23(20), 2839-2844, 1993
18. Hosoi et al, J. Biochem 117, 741-749 (1995); and
19. Ongkeko et al, "Inactivation of Cdc2 Increases the Level of Apoptosis Induced by DNA Damage"; Journal of Cell Science 108, 2897-2904 (1995).

We have enclosed a copy of PTO-1449 in duplicate which is considered part of the Information Disclosure Statement. This Information Disclosure Statement is being submitted prior to receipt of a first Office Action, so no fee is deemed necessary. However, if a fee is required, the Examiner is hereby authorized to charge our Deposit Account 50-0320.

Applicant respectfully requests that the Examiner consider and make of record the documents cited herein and that a copy of Form PTO-1449 be initialed by the Examiner and returned to the undersigned.

Respectfully submitted,

FROMMER LAWRENCE & HAUG LLP  
Attorneys for Applicants

By William F. Lawrence / s/ M. B. G.  
William F. Lawrence  
Reg. No. 28,029  
Tel. (212) 588-0800

Based on Form PTO-1449

ATTY. DOCKET NO.

SERIAL NO.

516745-2001.1

10/611,539

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

APPLICANT

Lal et al

FILING DATE

July 1, 2003

GROUP

1632

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	US 5,723,313	3-3-1998	Sherr et al			
	AB	US 5,733,920	3-31-1998	Mansuri et al			
	AC	US 5,849,733	12-15-1998	Kim et al			
	AD	US 5,116,954	5-26-1992	Briet et al			
	AE	US 5,284,856	2-8-94	Naik et al			
	AF	US H1427	4-4-1995	Briet et al			
	AG	US 4,900,727	2-13-1990	Kattige et al			

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
		WO 01/83469 A1	11-8-2001	PCT			YES NO

## OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	AH	Senderowicz et al, "Preclinical and Clinical Development of Cyclin-Dependent Kinase Modulators"; J. Natl. Cancer Institute, Vol. 92, No. 5, 2000, 376-387;
	AI	Naik et al, "An Anti-Inflammatory Cum Immunomodulatory Piperidinylbenzopyranone from <i>Dyoxylum Binectariferum</i> : Isolation, Structure and Total Synthesis"; Tetrahedron, 1998, 44(7), 2081-2086;
	AJ	Pérez-Roger et al, "Inhibition of Cellular Proliferation by Drug Targeting of Cyclin-Dependent Kinases"; Curr. Pharm. Biotechnol, 2000, July 1 (1), 107-116;
	AK	Losiewicz et al, "Potent Inhibition of CDC2 Kinase Activity by the Flavonoid L86-8275"; Biochemical and Biophysical Research Communications, 1994, 589-595;
	AL	J. Org. Chem. 1992, 57, 6321-6323;
	AM	Larget et al, "Convenient Extension of the Wessely-Moser Rearrangement for the Synthesis of substituted Alkylaminoflavones as Neuroprotective Agents in Vitro"; Bioorganic and Medicinal Chemistry Letters 10 (2000) 835-838;
	AN	Tsuritani et al; Organic Letters 2001, Vol. 3, No. 17, 2709-2711;
	AO	Bang-Chi-Chen et al, "A New Facile Method for the Synthesis of 1-Arylimidazoles-5-Carboxylates", Tetrahedron Letters 41 (2000) 5453-5456;
	AP	Falb et al, "A Convenient Synthesis of Chiral Oxazolidin-2-Ones and Thiazolidin-2-Ones and an Improved Preparation of Triphosgene"; Synthetic Communications, 23(20), 2839-2844, 1993
	AQ	Hosoi et al, J. Biochem 117, 741-749 (1995); and
	AR	Ongkeko et al, "Inactivation of Cdc2 Increases the Level of Apoptosis Induced by DNA Damage"; Journal of Cell Science 108, 2897-2904 (1995).

EXAMINER

DATE CONSIDERED

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Based on Form PTO-1449 (3/90)				ATTY. DOCKET NO. <b>516745-2001.1</b>		SERIAL NO. <b>10/611,539</b>	
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT <b>Lal et al</b>			
FILING DATE <b>July 1, 2003</b>				GROUP <b>1632</b>			

  

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	US 5,723,313	3-3-1998	Sherr et al			
	AB	US 5,733,920	3-31-1998	Mansuri et al			
	AC	US 5,849,733	12-15-1998	Kim et al			
	AD	US 5,116,954	5-26-1992	Briet et al			
	AE	US 5,284,856	2-8-94	Naik et al			
	AF	US H1427	4-4-1995	Briet et al			
	AG	US 4,900,727	2-13-1990	Kattige et al			

  

FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
		WO 01/83469 A1	11-8-2001	PCT			YES NO

  

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)		
	AH	Senderowicz et al, "Preclinical and Clinical Development of Cyclin-Dependent Kinase Modulators"; J. Natl. Cancer Institute, Vol. 92, No. 5, 2000, 376-387;
	AI	Naik et al, "An Anti-Inflammatory Cum Immunomodulatory Piperidinylbenzopyranone from <i>Dyoxylum Binectariferum</i> : Isolation, Structure and Total Synthesis"; Tetrahedron, 1998, 44(7), 2081-2086;
	AJ	Pérez-Roger et al, "Inhibition of Cellular Proliferation by Drug Targeting of Cyclin-Dependent Kinases"; Curr. Pharm. Biotechnol, 2000, July 1 (1), 107-116;
	AK	Losiewicz et al, "Potent Inhibition of CDC2 Kinase Activity by the Flavonoid L86-8275"; Biochemical and Biophysical Research Communications, 1994, 589-595;
	AL	J. Org. Chem. 1992, 57, 6321-6323;
	AM	Larget et al, "Convenient Extension of the Wessely-Moser Rearrangement for the Synthesis of substituted Alkylaminoflavones as Neuroprotective Agents in Vitro"; Bioorganic and Medicinal Chemistry Letters 10 (2000) 835-838;
	AN	Tsuritani et al; Organic Letters 2001, Vol. 3, No. 17, 2709-2711;
	AO	Bang-Chi-Chen et al, "A New Facile Method for the Synthesis of 1-Arylimidazoles-5-Carboxylates", Tetrahedron Letters 41 (2000) 5453-5456;
	AP	Falb et al, "A Convenient Synthesis of Chiral Oxazolidin-2-Ones and Thiazolidin-2-Ones and an Improved Preparation of Triphosgene"; Synthetic Communications, 23(20), 2839-2844, 1993
	AQ	Hosoi et al, J. Biochem 117, 741-749 (1995); and
	AR	Ongekeko et al, "Inactivation of Cdc2 Increases the Level of Apoptosis Induced by DNA Damage"; Journal of Cell Science 108, 2897-2904 (1995).

  

EXAMINER	DATE CONSIDERED
----------	-----------------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.